570 related articles for article (PubMed ID: 18753861)
21. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
22. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
[TBL] [Abstract][Full Text] [Related]
23. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
24. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
[TBL] [Abstract][Full Text] [Related]
25. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
26. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
27. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
28. [A study of the dosage and efficacy of entecavir for treating hepatitis B virus].
Yao GB; Zhang DF; Wang BE; Xu DZ; Zhou XQ; Lei BJ
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):484-7. PubMed ID: 16042878
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
[TBL] [Abstract][Full Text] [Related]
30. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
[TBL] [Abstract][Full Text] [Related]
33. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
34. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
Benhamou Y; Thibault V; Vig P; Calvez V; Marcelin AG; Fievet MH; Currie G; Chang CG; Biao L; Xiong S; Brosgart C; Poynard T
J Hepatol; 2006 Jan; 44(1):62-7. PubMed ID: 16274835
[TBL] [Abstract][Full Text] [Related]
36. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
37. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
38. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
Park HS; Lee DH; Heo J; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2006 Jun; 12(2):173-83. PubMed ID: 16804342
[TBL] [Abstract][Full Text] [Related]
40. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]